CureDuchenne Shares Updates from 29th Annual Congress of the World Muscle Society We’re at the 29th Annual Congress of the World Muscle Society this week and are pleased to share […]
As an early investor in Capricor Therapeutics, CureDuchenne is happy to share that Capricor has announced their intent to apply to the FDA for full approval of Deramiocel (CAP-1002) for […]
CureDuchenne is pleased to communicate that Wave Life Sciences announced positive interim data from the ongoing Phase 2 FORWARD-53 study in Duchenne amenable skipping exon 53. After 24 weeks of […]
As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive data from their Phase 1/2 trial of DYNE-251 in individuals with Duchenne amenable to skipping […]
Letter to the Duchenne Community – INSPIRE DUCHENNE update Dear Duchenne Community, We are writing to share an important update on INSPIRE DUCHENNE, our Phase 1/2 clinical trial of SGT-003 for […]
Avidity Biosciences, which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44. Their experimental exon-skipping agent, AOC […]
Link to press release We are thrilled to share the latest data from RegenXBio’s microdystrophin gene therapy, AFFINITY DUCHENNE®. RGX-202 is a one-time gene therapy for Duchenne designed to deliver […]
Pfizer Duchenne Program Discontinuation: Pfizer has officially decided to discontinue their microdystrophin gene therapy program for Duchenne, after the sad announcement last month that the Phase 3 trial failed to […]
First nonsteroidal treatment approved for patients six years of age and older with DMD regardless of genetic mutation now available in the U.S. ITF also announces the launch of ITF […]
